US 12,186,348 B2
Glycan strands and oligosaccharides derived from Streptococcus bacteria
Bindong Liu, Brentwood, TN (US); and Qiujia Shao, Brentwood, TN (US)
Assigned to Meharry Medical College, Nashville, TN (US)
Appl. No. 17/057,599
Filed by Meharry Medical College, Nashville, TN (US)
PCT Filed May 23, 2019, PCT No. PCT/US2019/033796
§ 371(c)(1), (2) Date Nov. 20, 2020,
PCT Pub. No. WO2019/226920, PCT Pub. Date Nov. 28, 2019.
Claims priority of provisional application 62/675,483, filed on May 23, 2018.
Prior Publication US 2021/0187042 A1, Jun. 24, 2021
Int. Cl. A61K 35/74 (2015.01); A61K 9/00 (2006.01); A61K 31/34 (2006.01); A61K 31/427 (2006.01); A61K 31/439 (2006.01); A61K 31/4418 (2006.01); A61K 31/513 (2006.01); A61K 31/52 (2006.01); A61K 31/537 (2006.01); A61K 31/5377 (2006.01); A61K 31/675 (2006.01); A61K 31/702 (2006.01); A61K 31/7072 (2006.01); A61K 31/715 (2006.01); A61K 38/16 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61K 47/60 (2017.01); A61P 31/18 (2006.01); C07H 3/06 (2006.01); C08B 37/00 (2006.01)
CPC A61K 35/74 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/34 (2013.01); A61K 31/427 (2013.01); A61K 31/439 (2013.01); A61K 31/4418 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61K 31/702 (2013.01); A61K 31/7072 (2013.01); A61K 31/715 (2013.01); A61K 38/162 (2013.01); A61K 38/212 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61P 31/18 (2018.01); C07H 3/06 (2013.01); C08B 37/0003 (2013.01)] 16 Claims
 
1. A method of treating one or both of HIV and HBV in a subject in need thereof, comprising: administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a glycan strand comprising GlcNAc-MurNAc (G-M), MurNAc-GlcNAc-MurNAc (M-G-M), and GlcNAc-MurNAc-GlcNAc-MurNAc (G-M-G-M).